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Objective: We performed a review of a consecutive series of 487 patients undergoing
the Ross operation to identify surgical techniques and clinical parameters that affect
outcome.
Methods: We performed a prospective review of consecutive patients from August
1986 through June 2002 and follow-up through August 2004. Patient age was 2
days to 62 years (median, 24 years), and 197 patients were less than 18 years of
age. The Ross operation was performed as a scalloped subcoronary implant in 26 pa-
tients, an inclusion cylinder in 54 patients, root replacement in 392 patients, and root–
Konno procedure in 15 patients. Clinical follow-up in 96% and echocardiographic
evaluation in 77% were performed within 2 years of closure.
Results: Actuarial survival was 82% 6 6% at 16 years, and hospital mortality was
3.9%. Freedom from autograft failure (autograft reoperation and valve-related death)
was 74%6 5%. Male sex and primary diagnosis of aortic insufficiency (no prior aor-
tic stenosis) were significantly associated with autograft failure by means of multivar-
iate analysis. Freedom from autograft valve replacement was 80% 6 5%. Freedom
from endocarditis was 95%6 2%. One late thromboembolic episode occurred. Free-
dom from allograft reoperation or reintervention was 82% 6 4%. Freedom from all
valve-related events was 63% 6 6%. In children survival was 84% 6 8%, and free-
dom from autograft valve failure was 83% 6 6%.
Conclusions: The Ross operation provides excellent survival in adults and children
willing to accept a risk of reoperation. Male sex and a primary diagnosis of aortic
insufficiency had a negative effect on late results.
D
issatisfaction with available options for aortic valve replacement in children
and young adults led us to initiate the use of the Ross operation in August
1986. Clinical evaluation and echocardiographic surveillance at completion
of the operation, 3 months postoperatively, 6 months postoperatively, and annually
thereafter was planned. Although the initial operations were done as scalloped sub-
coronary implants, we rapidly changed to the modified subcoronary implant or root
replacements in selected patients. Subsequent success with the root replacement led
to its use in almost all patients. The use of the Ross operation has expanded to patients
with complex left ventricular outflow tract obstruction, patients with active endocar-
ditis, and the newborn. Prior reviews of this prospective study identified mechanisms
of early failure and led to alterations in the procedure for management of patients with
significant aortic insufficiency (AI), aortic annular dilation, and ascending aortic
disease.1,2
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AGI 5 autograft valve insufficiency
AI 5 aortic insufficiency
ALF 5 allograft valve failure
AS 5 aortic stenosis
BSA 5 body surface area
CI 5 confidence interval
GEE 5 generalized estimating equation
HR 5 hazard ratio
VSD 5 ventricular septal defect
This article addresses questions about the durability and
operative risk of the Ross operation and the preferred opera-
tive technique, in particular the risk of progressive dilation of
the autograft root and failure of the allograft reconstruction of
the right ventricular outflow tract. We report the long-term re-
sults at a single institution during the period when use of the
Ross operation expanded worldwide and seek to identify op-
erative techniques and patient characteristics associated with
survival and autograft valve durability.
Materials and Methods
All 487 patients having a Ross operation at the University of
Oklahoma Health Sciences Center between August 1986 and July
2002 were entered into a prospective database, which was queried
as of August 2004. Surgeons offered the Ross operation to all chil-
dren, young adults with isolated aortic valve disease, and older
adults with an active lifestyle and a desire to avoid postoperative
anticoagulation. Children and young adults with significant abnor-
malities of the autologous pulmonary valve were not candidates
and were managed with allograft aortic valve replacement. Noncan-
didate adults were managed with a prosthetic valve or an allograft
valve based on their choice.
The numbers of Ross operations and of all other aortic valve
replacements for each year of the study are shown in Figure E1.
Patient characteristics and preoperative clinical information are
summarized in Table 1. The autograft valve was inserted as a mod-
ified scalloped subcoronary implant in 26 patients, an inclusion cyl-
inder in 54 patients, a root replacement in 392 patients, and a root–
Konno procedure in 15 patients. The right ventricular outflow tract
was reconstructed with a pulmonary allograft in 484 patients and an
aortic allograft in 3 patients for whom a pulmonary allograft was un-
available. Operative findings concerning aortic valve morphology,
aortic annulus dilation, or disease of the ascending aorta and man-
agement of these abnormalities are listed in Table 2.
Clinical follow-up was obtained by means of annual clinic visits
or communication with the referring cardiologist or the patient’s
personal physician. When physician contact was unavailable, direct
communication with the patient or family was attempted. Follow-up
was complete within 1 year of the study’s closure in 61% of the
patients and within 2 years of closure in 96% of the patients. The
follow-up represents a total of 3263 patient-years.
Annual echocardiographic surveillance after the first postoper-
ative year was planned. However, with continued follow-up, many
patients’ physicians elected to obtain echocardiograms every 2 or 3624 The Journal of Thoracic and Cardiovascular Surgery c Sepyears when their clinical evaluation did not indicate the need for
annual assessment. Echocardiograms obtained at the University
of Oklahoma Health Sciences Center were reviewed by echocardi-
ographers with a special interest in the patients undergoing the
Ross operation. Echocardiograms obtained from outside physi-
cians were reread at the University of Oklahoma Health Sciences
Center if they reported significant alteration in autograft or allo-
graft function. Autograft valve insufficiency (AGI) was graded
by using the thickness of the regurgitant stream relative to the
size of the left ventricular outflow tract3 (0, none or trivial; 11,
mild; 21, moderate; 31, moderate–severe; and 41, severe).
Patient migration, loss of health insurance, or both decreased
late echocardiographic surveillance. Echocardiographic assessment
was available within 2 years of study closure in 2004 in 77% of
the patients.
All analyses were performed with SAS System software, version
9.1 (SAS Institute, Inc, Cary, NC). Actuarial survival estimates of
freedom from postoperative events were calculated by using Ka-
plan–Meier method, with differences assessed with the Wilcoxon
and log-rank tests. All P values are reported. Cox multiple propor-
tional hazards regression analyses were applied to time to autograft
valve failure (AGF) and allograft valve failure (ALF).
Two-dimensional echocardiographic measurements of the diam-
eter of the autograft root or autograft sinus (in millimeters) were
recorded over time for each patient. Each measurement was
TABLE 1. Demographics and preoperative clinical
information (487 patients)
n %
Age: 1 d to 62 y; median, 24 y
Children: 1 d to 18 y 197 40
Young adults: 18 y to 50 y 251 52
$50 y 39 8
Sex: 360 male subjects and 127 female subjects;
ratio 2.8:1
Preoperative aortic valve disease
AI 154 32
AS 91 19
Mixed (AI/AS) 238 49
Other (replacement of normal prosthetic valve) 4 ,1
Previous median sternotomy 168 35
Previous aortic valve surgery 162 34
Previous aortic valve replacement 38 8
Aortic balloon valvuloplasty 48 10
Aortic valve endocarditis 40 8
Active 24 5
Primary hemodynamic aortic valve abnormality
Aortic insufficiency*:
138 male subjects and 29 female subjects;
ratio 4.8:1
167 34
Aortic stenosis:
222 male subjects and 98 female subjects;
ratio 2.3:1
320 66
AI, Aortic insufficiency; AS, aortic stenosis. *Patients with AI without prior
history of AS (ie, patient with AI after aortic valvotomy or valvuloplasty clas-
sified as AS).tember 2008
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CDz-transformed by using a regression equation4,5 that predicts the
mean and standard deviation (root mean square of regression) for
the diameter of the aortic sinuses of Valsalva for a given body sur-
face area (BSA). BSAs were calculated by using the technique of
Haycock and colleagues.6 The z-transformed autograft sinus diam-
eters were subjected to longitudinal analysis in a general linear
mixed model that accounted for correlation among an individual’s
measurements over time. The analysis was restricted to 383 patients
who underwent a root replacement, for whom we collected 2147
echocardiographic measurements of root size. The model predicted
z-transformed diameters after adjusting for a variety of fixed (be-
tween-subject) effects that appear to influence either sinus diameter
at the time of surgical intervention or the rate of increase in diameter
over time. Effects considered were age, sex, valve morphology, pre-
operative active endocarditis, primary hemodynamic lesion of aortic
stenosis (AS) or AI (no prior AS), ventricular septal defect (VSD;
subaortic), coarctation, ascending aortic dilation or aneurysm, prior
median sternotomy, prior aortic valve replacement, annular fixation,
aortic balloon valvuloplasty, and severity of AGI at completion of
the operation. A backward selection technique eliminated variables
until those remaining were significant.
Population-average changes in AGI over time were modeled with
generalized estimating equations (GEEs) in the 469 operative survi-
vors (3654 echocardiograms). Postoperative observations were trun-
cated at the date of autograft reoperation for 38 patients, 10 of whose
reoperations were unrelated to AGI. Predictions were calculated with
SAS PROC GENMOD by specifying a cumulative logit model that
accounted for repeated observations within subjects. Changes over
time in AGI were investigated for the following predictors of out-
come: implant technique, age (as a continuous variable), sex, aortic
valve morphology, preoperative active endocarditis, primary preop-
erative hemodynamic lesion of AS or AI (no prior evidence of AS),
VSD (subaortic), coarctation, ascending aortic dilation or aneurysm,
prior median sternotomy, previous aortic valve replacement, annular
fixation, aortic balloon valvuloplasty, and severity of AI at the com-
pletion of operation. These variables were entered simultaneously
into the longitudinal model and then eliminated one by one until
all variables remaining had a P value of .1 or less.
TABLE 2. Operative clinical information for 487 patients
n %
Valve morphology
Congenital bicuspid or unicuspid aortic
valve (initial operation)
409 84
Tricuspid aortic valve 78 16
Operative findings
Aortic annulus dilatation* 167 34
Aneurysm or significant dilation of ascending aortay 164 34
Operative management
Aortic annulus reduction and fixation 164 34
Fixation of aortic annulus with synthetic cuff 218 45
Replacement of ascending aorta 100 21
Aortoplasty 60 12
Resection of dilated aorta 4 1
*Aortic annulus diameter greater than predicted diameter by 2 mm. yAortic z
value greater than 2 or diameter greater than 40 mm.The Journal of ThoResults
Survival
Hospital mortality was 3.9% (19/487). There were 15 late
deaths, 7 of which were not cardiac related, 2 of which were
valve related, and 6 of which were sudden unexplained deaths
counted as valve related. Actuarial survival for all causes was
92%6 2% at 10 years and 82%6 6% at 16 years (Figure E2).
Actuarial survival from operative or valve-related death was
94% 6 1% and 89% 6 4% at 10 and 16 years, respectively.
In patients less than 18 years of age, hospital mortality was
5.6% (11/197). Actuarial survival (all causes) was 92% 6
2% and 84% 6 8% at 10 and 16 years, respectively, and
that from all operative and valve-related deaths was 94% 6
2% at both 10 and 16 years. There were no late deaths associ-
ated with autograft valve or allograft valve reoperation.
Survival (all causes) among the 487 patients was compared
with the survival of the general US population, matched by
each patient’s age, sex, and year of operation (Figure 1). After
the initial decrease associated with early hospital deaths, the
survival appears to parallel the survival of the matched popu-
lation to 13 years. After 13 years, the number of patients avail-
able for comparison is less than 10% of the surgical cohort.
The confidence limits of the cohort’s survival curve widen,
limiting the validity of the later comparisons.
Autograft Valve Failure
AGF was defined as autograft valve reoperation or valve-re-
lated death. Actuarial freedom from AGF was 86%6 2% and
74% 6 5% at 10 and 16 years, respectively. Actuarial free-
dom from AGF in 462 patients (excluding those with an ab-
normal pulmonary valve or SLE) was 90%6 2% and 83%6
5% at 10 and 16 years, respectively. Actuarial freedom from
AGF in the 186 children was 88%6 3% and 83%6 6% at 10
and 16 years, respectively.
AGF occurred in 46 patients (38 autograft valve reopera-
tions, 2 valve-related deaths, and 6 sudden unexplained
Figure 1. Survival (all causes) among the 487 patients compared
with survival of the US population matched for each patient's
age, sex, and year of operation.racic and Cardiovascular Surgery c Volume 136, Number 3 625
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the primary causes for AGF requiring reoperation and the in-
cidence of reoperation by initial operative technique. Auto-
graft valve replacement was required in 27 of the 38
autograft valve reoperations, and the actuarial freedom
from autograft valve replacement was 90% 6 2% and 80%
6 5% at 10 and 16 years, respectively.
Univariate Kaplan–Meier analyses identified male sex,
primary lesion of AI, and type I VSD as potential risk factors
for the development of AGF. Prior aortic valve surgery was
protective against AGF. Multivariable analyses with propor-
tional hazards regression confirmed male sex and primary le-
sion of AI as the only factors associated with an increased risk
of AGF (Table 4, A). Predicted freedom from AGF by sex
and primary lesion for the proportional hazards model are
shown in Figure 2. Patients with primary AI had approxi-
mately 3 times the risk for AGF compared with patients
TABLE 3. Autograft reoperation (38 patients)
By initial operative technique:
21/389 Root replacements
12/53 Inclusion cylinder
5/26 Scalloped subcoronary
29/409 Bicuspid or unicuspid
9/78 Tricuspid
Causes for reoperation
27 Autograft replacement Bicuspid Tricuspid
7 Annulus dilation 4 3
5 Sinus dilation 4 1
5 Endocarditis 3 2
3 Technical 1 2
5 Abnormal pulmonary valve
autograft (3 bicuspid,
1 quadricuspid,
1 abnormal commissure)
5
1 Cusp prolapse 1
1 Recurrent SLE 1
11 Autograft repair
7 Annulus dilation
2 Sinus dilation
2 Subvalve AS (1 recurrent)
SLE, Systemic lupus erythematosus; AS, aortic stenosis.
TABLE 4. A. Variables associated with autograft valve
failure
Univariate Hazard ratio Multivariate
Variable P value (95% CI) P value
Primary lesion, AI .001 2.9 (1.5–5.7) .0020
Sex, male .019 3.1 (1.1–8.8) .0361
VSD type 1 (subaortic) .002
CI, confidence interval; AI, aortic insufficiency; VSD, ventricular septal
defect.626 The Journal of Thoracic and Cardiovascular Surgery c Sepwith AS, and the risk for male subjects was approximately
3 times that of female subjects.
In 164 patients with primary AI, actuarial freedom from
AGF was 59% 6 10% at 15 years, which was significantly
less than that of 304 patients with AS whose actuarial free-
dom from AGF was 82% 6 6% at 15 years (P 5 .02 Wil-
coxon test; P , .01, log-rank test). Recognizing the
increased incidence of autograft degeneration in patients
with AI, we elected in 1995 to institute annulus reduction
and fixation in adults and older children with aortic annulus
dilation (aortic annulus .27 mm or z value .2 for annulus
compared with BSA). Annulus reduction and fixation was
used in 96 patients with primary AI, for whom actuarial free-
dom from AGF was 87%6 8% at 10 years. These results are
similar to those of patients with a primary diagnosis of AS
(ie, 92% 6 2% for the same time period).
Autograft Root Dilation
Figure E3 displays the z-transformed autograft sinus or root di-
ameter for all of the patients (383 operative survivors) who had
a root replacement over time. Figure E4 displays mean ob-
served and predicted values (derived from a general linear
mixed model) for z-transformed autograft sinus or root diam-
eters in this patient group. Although we planned to perform
echocardiographs at specific postoperative intervals, the pro-
cedures’ actual timing varied considerably. Observations
were grouped to use each patient’s multiple echocardiographic
studies to calculate mean diameters at defined intervals.
The observed baseline (time5 0) mean z value of 1.976
1.88 increases to a z value of 3.15 6 2.18 at 1 year after the
operation. Change thereafter is gradual. A general linear
mixed model yielded estimates of aortic diameter that
accounted for correlations among patients’ repeated measure-
ment over time. The predicted baseline z diameter of 1.96 is
adjusted downward by 0.04 z units for each year of a patient’s
age at the time of the operation. Patients with a primary lesion
Figure 2. Predicted freedom from autograft failure by sex and for
primary lesion for the proportional hazard model.tember 2008
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(P 5 .0026). Male subjects’ baseline diameters are 0.40
z units larger than those of female subjects (P 5 .0389).
The cohort included 30 patients with a subaortic VSD, whose
diameters were marginally larger (1.35 z units, P5 .058). No
factors were associated with smaller baseline diameters.
The model separately estimated the rate of change in aortic
diameter over the first 12 months and after 12 months. Diam-
eter increased by 0.13 z units per month during the first 12
months. The predicted rate of change after 12 months is
0.019 z units per month (standard error, 0.0086; 95% confi-
dence limit, 0.003–0.036).
Four factors were associated with a more rapid increase in
diameter over the first 12 months: grade 2 (but not grade 1)
baseline AI (an additional increase of 0.18 z units per month,
P 5 .0249), bicuspid aortic valve (an additional 0.09 z units
per month, P5 .0010), a history of coarctation (an additional
0.09 z units per month, P 5 .0131), and repair of an aortic
aneurysm as part of a Ross operation (an additional 0.06 z
units pre month, P5 .0047). After 12 months, these 4 factors
were not associated with differences in the overall predicted
rate of change of 0.019 z units per month.
Patients who had cuff fixation of their aortic annulus had
a rate of change in aortic diameter over the first 12 months
that was 0.058 z units per month slower than the others
(P 5 .0086). After 12 months, their rate of change was
0.019 z units per month faster than (or about double the
rate of those) without cuff fixation (P 5 .0005). We also in-
vestigated but found no interaction between sex and primary
lesion of AI (P5 .9) or between the bicuspid aortic valve and
aneurysm (P 5 .4) with respect to rate of change in aortic
diameter.
Figure 3. Observed and predicted probabilities of autograft valve
insufficiency over time. Predicted percentages of aortic insuffi-
ciency (AI) grade (solid line) are obtained from an ordinal longitu-
dinal (generalized estimating equation) model and sum to 100% at
a given time of follow-up. The predicted percentage of patients
with no AI (grade 0) decreases, whereas other grades gradually
increase in time.The Journal of ThoValve Function
Changes over time in the severity of AGI, as observed and
predicted by GEEs, are shown in Figure 3. Because few pa-
tients had moderate–severe (31) or severe (41) AGI, these
groups were combined for analysis. The predicted probability
of no or trivial (grade 0) AGI decreased from 63% in the early
postoperative period to 52% at 5 years, 36% at 10 years, and
24% at 16 years. The predicted probability of mild (grade 1)
and moderate (grade 21) AGI increased, with 50% having
mild and 17% having moderate insufficiency at 16 years. A
separate GEE analysis that focused only on the development
of moderate–severe (31) and severe (41) AGI is shown in
Figure 4. Predicted 31 or 41 AGI slowly increased to
3.3% (70% confidence interval [CI], 2.7%–4%) at 5 years,
7.9% (70% CI, 5.8%–9.5%) at 10 years, and 21.5% (80%
CI, 15.3%–29.4%) at 16 years.
Independent variables associated with development of
moderate–severe or severe autograft insufficiency were deter-
mined by means of GEE analysis. In addition to the time
elapsed since the operation, other associated factors were
an immediate postoperative AI of grade 1 or higher and the
patient’s age at the time of the operation. The association of
operative technique (intra-aortic implant versus root replace-
ment) was marginal once the other variables were accounted
for. Previous aortic valve replacement was associated with
a decreased risk of 31 or 41 AGI (Table 4, B).
Endocarditis
Actuarial freedom from endocarditis was 95% 6 2% at 16
years. Endocarditis occurred in 11 patients; 6 involved the
autograft valve, 1 involved the mitral valve, and 4 involved
the allograft valve. Autograft valve endocarditis occurred
perioperatively in 1 patient, 2.7 years postoperatively in a pa-
tient with AGI, and in 4 patients (6 episodes at 4.1–10.1
Figure 4. Predicted probabilities of 31 (moderate–severe) or 41
(severe) autograft valve insufficiency (AGI) by means of general-
ized estimating equations over time. AGI slowly increases from
3.3% (70% confidence interval, 2.7%–4%) at 5 years to 21.5% (con-
fidence interval, 15.3%–29.4%) at 16 years.racic and Cardiovascular Surgery c Volume 136, Number 3 627
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had fungal endocarditis, 1 related to delayed treatment of me-
diastinitis and 1 after multiple operative procedures for recur-
rent allograft obstruction. Allograft endocarditis occurred 2.7
years postoperatively as a result of intravenous drug use in
1 patient and 11 years postoperatively in a patient with mod-
erate allograft obstruction.
Thromboembolism
Thromboembolism was identified in only 1 patient who had
a nonfatal coronary embolism during treatment for endocar-
ditis. Six patients died suddenly and were presumed to repre-
sent valve-related deaths. One or more of these deaths might
have been an unrecognized episode of thromboembolism.
Anticoagulation was used only in patients who had an asso-
ciated mitral valve procedure that required anticoagulation.
Allograft Valve Failure
ALF was defined as allograft valve reoperation or interven-
tion. Actuarial freedom from ALF was 90%6 2% at 10 years
and 82% 6 4% at 16 years. Multivariable proportional haz-
ard regression identified younger age at operation (P 5 .02;
hazard ratio [HR], 0.97; 95% CI, 0.94–0.1), previous aortic
valve replacement (P , .0001; HR, 6.23; 95% CI, 2.72–
14.28), history of bacterial endocarditis (P 5 .002; HR,
4.58; 95% CI, 1.75–11.98), and male sex (P 5 .01; HR,
4.01; 95% CI, 1.39–11.56) as independent risk factors for in-
creased ALF. Allograft valve replacement or intervention
was required in 33 patients. Accelerated ALF within 1 year
of allograft insertion occurred in 3 patients.
A number of patients with significant obstruction of the
allograft conduit or allograft valve insufficiency are being
followed. Allograft degeneration was defined as allograft
reoperation or intervention, a peak allograft gradient of 50
TABLE 4. B. Variables associated with developing
moderate–severe (grade 3) or severe (grade 4) autograft
valve insufficiency (according to a GEE model based on
cumulative logits)
Univariate Odds ratio Multivariable
Variable P value (95% CI) P value
Postoperative AGI,
grade 11 or higher
.003 2.7 (1.2–6.1) .0176
Intra-aortic implant
(vs root replacement)
.0043 2.5 (1.0–6.6) .0554
Follow-up time
(in 1-mo increments)
,.0001 1.01 (1.00–1.02) .0017
Age (in 1-y increments) .0255 1.03 (1.01–1.06) .0088
Previous aortic
valve replacement
.0398 0.10 (0.01–0.79) .029
Previous aortic valve replacement is protective. GEE, Generalized estimat-
ing equation; CI, confidence interval; AGI, autograft valve insufficiency.628 The Journal of Thoracic and Cardiovascular Surgery c Semm Hg or more, or severe allograft valve insufficiency. Ac-
tuarial freedom from allograft degeneration was 81% 6 3%
and 71%6 5% at 10 and 16 years, respectively. Balloon val-
vuloplasty, stent placement, or both was performed in 7 pa-
tients, and in 5 of these, allograft replacement has not been
required for up to 8 years after the intervention. Repeat inter-
vention was required on 2 occasions in 2 patients.
Valve-related Morbidity
Valve-related morbidity is defined as AGF, ALF, endocardi-
tis, and valve-related death. Actuarial freedom from valve-re-
lated morbidity was 80%6 3% and 63%6 6% at 10 and 16
years, respectively.
Discussion
The Ross operation has the advantages of a viable valve, ex-
cellent hemodynamics, freedom from hemolysis, no pros-
thetic valve sounds, growth in young children, and a low
risk of endocarditis. However, the operation requires recon-
struction of the right ventricular outflow tract with a nonvia-
ble valve and is a technically demanding operation with an
increased operative risk and concern for the durability of
the autograft valve. Debate continues about the most effica-
cious operative technique for implantation of the autograft
valve, about patient selection, and about the most suitable
replacement device for the transplanted pulmonary valve.
Operative Technique
The root replacement is the most versatile technique, allow-
ing the surgeon to replace the aortic valve in patients of
any age and to manage complicated left ventricular outflow
tract obstructions. If the patient’s pulmonary valve is normal,
this technique is most likely to provide the patient with a com-
petent autograft valve with minimal AGI at completion of the
operation. The operation has an increased risk of intraopera-
tive bleeding and a risk of malalignment of the coronary
arteries at the time of implantation to the autograft root.
Our experience raises several technical and patient selec-
tion concerns. Autograft insufficiency was the most common
cause of autograft reoperation. The most common cause of
autograft insufficiency was late dilation of the autograft annu-
lus, particularly in patients with AI as their primary lesion.
We presently use aortic annulus fixation with synthetic mate-
rial or glutaraldehyde-fixed pericardium in all older adoles-
cents and adults whose BSA-standardized aortic annulus
approaches a normal diameter. We reduce the aortic annulus
if it is dilated. The only independent predictors of develop-
ment of moderate–severe or severe AGI were increasing
age at the time of the operation and AGI at completion of
the operation and increasing follow-up time. Previous aortic
valve replacement was protective.
Careful inspection of the pulmonary valve is essential be-
fore proceeding with a Ross operation. Use of a pulmonary
valve with minor abnormalities will likely accelerate failure.ptember 2008
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monary valves had minor abnormalities all required replace-
ment of the autograft valve at 2.9 to 8.5 years, with a median
of 4 years. Still, use of the valve is acceptable in some very
young children or adolescents in whom other alternatives
are less acceptable.
Our experience supports the use of the Ross operation in
the management of patients with aortic valve endocarditis.
Forty patients had endocarditis that led to aortic valve re-
placement, and in 24 patients it was active. In patients with
active endocarditis, appropriate antibiotic therapy was com-
pleted after surgical intervention, and late endocarditis was
identified in 5 patients, all related to recurrent intravenous
drug use. The Ross operation was remarkably free of hospi-
tal-acquired endocarditis, which occurred in only 1 patient
because of an infected central venous catheter.
Recent concern centers on autograft failure caused by au-
tograft root dilation, especially in patients with a bicuspid
aortic valve.7 In our series aortic valve morphology was
not a risk factor for AGF by means of univariate or multivar-
iate analysis.
Using echocardiographic standards for aortic sinus and
root diameters, several authors have identified significant in-
creases in autograft sinus and root diameters,8-10 whereas
others have shown limited dilation after the first postopera-
tive year.11,12 The use of echocardiographic standards for
the aortic root or sinuses might not be appropriate. Many
adults and children have autograft sinus or root diameters
that exceed the accepted aortic diameters early, when the au-
tograft root distends at systemic pressure. Our general linear
mixed-model analyses of z-transformed aortic sinus or root
diameters demonstrated that bicuspid aortic valve, repair of
an ascending aortic aneurysm, grade 2 early postoperative
AI, and history of a subaortic VSD were associated with
more rapid increases in diameter during the first 12 months
of follow-up. However, after 12 months, patients displaying
these characteristics exhibit very gradual changes in diameter
that do not differ from those of the overall group.
The optimal timing for autograft reoperation for dilation is
unclear. Recently, Ergin and colleagues13 and Gleason and as-
sociates14 have suggested that elective operation on the dilated
ascending aorta should be based on a ratio of observed to pre-
dicted diameter rather than the absolute size. They suggest a ra-
tio of 1.5 as an indication for replacement of a degenerative
aorta with or without AI or at the time of other cardiac surgery
comparedwith a ratio of1.3 for anelectiveoperation in a patient
with Marfan syndrome. Autograft root dissection is rare, with
only 5 reported cases,1,5,15-19 and we have recently performed
a reoperation on a patient with severe autograft insufficiency
and a 5.3-cm autograft root and identified an unexpected
chronic dissection. Autograft rupture has not been reported.
Accepting the suggestions of Ergin and colleagues13 and
Gleason and associates14 and using the equations that Roman
and coworkers20 developed to predict diameters for the aorticThe Journal of Thoroot and sinus of Valsalva from BSA, we identified 86 patients
in our series with at least 1 ratio (echocardiographically mea-
sured diameter/predicted diameter) greater than 1.5. Forty-
seven patients had 2 or more ratios greater than 1.5. The trajec-
tories of these individual patients are shown in Figure E5.
Although most demonstrate consistent ratios over time,
a few have progressive increases in their ratios and might be
candidates for elective replacement of their autograft root by
a valve-sparing operation or a root replacement. These sug-
gestions are in contrast to those of Luciano and Mazzuco.21
Our data suggest that male subjects with primary AI have
an increased risk for autograft failure and might have an in-
creased risk of reoperation, but they are not at a greater risk
for autograft root dilation. The excellent survival and absence
of thromboembolism or hemorrhage complications and
a very low risk of endocarditis might warrant recommenda-
tion of a Ross operation, but the patient must be made aware
of the likely increased risk of reoperation.
Increasing concern about the incidence of dilation of the
autograft root has caused many surgeons to reconsider the
subcoronary implant or the inclusion cylinder technique.
The use of the subcoronary and inclusion techniques requires
careful matching of the size of the autograft root to the aortic
annulus size, the sinus diameter, and the sinotubular diameter
of the aortic root. The autograft root is very distensible, and
its size is probably best calculated from measurement of
the diameter of the sinotubular ridge of the pulmonary
root.22 The subcoronary and inclusion cylinder techniques
cannot be used in patients who require replacement or recon-
struction of the proximal aortic root or in patients who require
a Ross–Konno procedure for management of left ventricular
outflow tract obstruction. Also, infants and young children
can rarely have a Ross operation as a subcoronary implant
or as an inclusion cylinder because of the small size of the
aortic annulus.
Reconstruction of the Right Ventricular Outflow
Tract
Pulmonary allografts were our choice for reconstruction of
the right ventricular outflow tract. We based allograft size
on patient age and used an allograft that was larger than the
predicted pulmonary valve size based on BSA. When possi-
ble, allografts from donors with the blood type of the recipi-
ent were used. Previous multivariate analysis has shown
young donor age, later year of operation, and non-Ross oper-
ation as risk factors for allograft failure.23 Raanani and asso-
ciates24 identified younger donor age, shorter duration of
cryopreservation, and smaller allograft size as independent
predictors of late allograft stenosis in 109 patients undergo-
ing the Ross operation. Both of these studies suggest that
an immune-mediated response can be associated with allo-
graft failure. Accelerated allograft failure caused by an im-
mune-mediated response has been demonstrated in aortic
allografts25 and pulmonary allografts in children.26racic and Cardiovascular Surgery c Volume 136, Number 3 629
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tricular outflow tract reconstruction have been introduced.
Novick and colleagues27 have had early good results with
the use of the freestyle porcine aortic root in 11 patients under-
going the Ross operation. Purohit and coworkers28 reported
good early results in 20 patients undergoing the Ross opera-
tion using the Contegra bovine jugular vein conduit for right
ventricular reconstruction. Results with both approaches are
encouraging, but significant follow-up must be obtained
before their adoption as an improvement over the allograft.
Conclusion
The Ross operation remains an excellent choice for the child
or young adult requiring aortic valve replacement. It provides
excellent survival and hemodynamics in most patients, with
limited effect on lifestyle. Its only significant valve-related
morbidity is the development of AGF or ALF requiring reop-
eration. Survival and valve-related morbidity in this series of
Ross operations compared favorably with contemporary re-
ported patient outcomes of aortic mechanical and stented bio-
prosthetic valves,29,30 although this comparison is limited by
our inability to have complete echocardiographic follow-up.
The only clinical parameters that clearly affect autograft
degeneration are male sex and a primary diagnosis of AI.
Aortic annulus fixation and reduction, when indicated, ap-
pear to delay the occurrence of autograft failure and might re-
duce the incidence. The role of sinotubular junction fixation,
advocated by some, was not addressed in this study. Auto-
graft root dilation remains a concern and might limit the
xapplicability of the root replacement. Presently accepted
standards for replacement of a dilated degenerative ascending
aorta might be too conservative for the autograft root. Allo-
grafts remain the gold standard for right ventricular recon-
struction. However, the development of a viable and
durable means of reconstruction of the right ventricular out-
flow tract is needed. Lifetime echocardiographic surveillance
should be maintained on all patients.
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CDFigure E1. A, Aortic valve replacements in adults, Ross opera-tions, and all others at University of Oklahoma Health Sciences
Center, August 1986 through June 2002. B, Aortic valve replace-
ments in children, Ross operations in children, and all others at
University of Oklahoma Health Sciences Center, August 1986
through June 2002.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 3 630.e1
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CDFigure E2. Actuarial survival from all causes and from valve-re-
lated deaths in 487 patients having a Ross operation, August
1986 through June 2002 as of August 2004.630.e2 The Journal of Thoracic and Cardiovascular Surgery c September 2008
Elkins et al Surgery for Acquired Cardiovascular Disease
A
CDFigure E3. The z-transformed autograft sinus or root diameter of
all 2147 echocardiograms obtained in 383 operative survivors
over time. All calculated z scores are displayed (1) for each
individual patient and connected by a line ending with the last
follow-up. Significant variation occurred with the z scores of
each individual patients over time related to variation in echocar-
diographic diameters measured and in some caused by increases
in body surface area.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 3 630.e3
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A
CDFigure E4. Mean observed and predicted z-transformed autograft
sinus or root diameters. Observed mean diameters are calculated
from individual patient means so that, for example, the mean at
time zero represents all echocardiograms performed up to the
third month. Means displayed for 0.5, 1, and 1.5 years include
echocardiograms performed within 3 months of these time points.
The mean reported at 2 years aggregates information from echo-
cardiograms performed between 21 and 30 months after the oper-
ation. Means reported for 3 to 10 years of follow-up use all
echocardiograms performed within 6 months. The mean reported
for 12 years use all studies reported within 12 months. The small
numbers available after 12 years of follow-up are shown individ-
ually. The predicted mean scores are derived from the general lin-
ear mixed model. The observed baseline (time 5 0) mean z value
of 1.976 1.88 increases to a z value of 3.156 2.18 at 1 year after the
operation. Change thereafter is gradual.630.e4 The Journal of Thoracic and Cardiovascular Surgery c September 2008
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A
CDFigure E5. A, Individual plots over time of the calculated ratio of
measured autograft diameter/predicted aortic diameter (by body
surface area) for each patient (86) with a ratio of 1.5 or more. Con-
sistent progressive increase in diameter was rarely identified. B,
Individual plots over time of the calculated ratio of measured au-
tograft diameter/predicted aortic diameter (body surface area) for
each patient (45) with a ratio of 1.5 or greater on more than 1 echo-
cardiogram. Some of these patients have shown a consistent
increase in the value of their ratio and might be candidates
for elective surgical intervention.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 3 630.e5
